System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maurice Pérol is an expert in Oncology at Centre Léon Bérard (France). As of November 2026, ScienceLeadR ranks Maurice Pérol in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Maurice Pérol has authored 606 publications, the most recent in 2026, and is an investigator in 62 clinical trials, 24 of them ongoing. SLR score: 2,769 (community average: 125). How the SLR is computed.

LeadR Profile

Maurice Pérol Centre Léon Bérard France
2 769 ScienceLeadR Reputation 2769

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Centre Léon Bérard

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 606

Citations

Citations: 39 460 1st author: 50 Last author: 67 Unique author: 23

Main journals

Ann Oncol 78
J Thorac Oncol 68
Rev Mal Respir 57
J Clin Oncol 55
Lung Cancer 46

Best Journals

Ann Oncol 46
J Clin Oncol 29
N Engl J Med 14

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
T-cell engagers in small-cell lung cancer: current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation Workshop.
PMID 42962497 — cells, lung, neoplasms, lung neoplasms, small cell lung carcinoma, united states food and drug administration, foundations, therapeutics, t-lymphocytes		Cancer Treat Rev20260
Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities.
PMID 42722608 — lung, hospitalization, melanoma, neoplasms, immune checkpoint inhibitors, lung neoplasms		Bull Cancer20260
Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.
PMID 42929702 — cells, lung, progression-free survival, neoplasms, maintenance, lung neoplasms, small cell lung carcinoma, therapeutics, ligands		N Engl J Med Top journal20261
Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
PMID 42691832 — cells, lung, protein isoforms, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics		Lung Cancer20260
Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.
PMID 42662853 — cells, lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, immunotherapy, denosumab, lung neoplasms, small cell lung carcinoma, sex, therapeutics, tissues, mutation		J Bone Oncol20260

Clinical Studies 62

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Chair: 1

By phase:

Phase 3 37
Phase 2 17
N/A 6
Phase 1 2

By status:

Completed 27
Recruiting 17
Active not recruiting 14
Not yet recruiting 2
Suspended 1
Terminated 1

By type:

Interventional 58
Observational 4

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 4
multicentricup10 51

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

24 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib		Phase 3Active not recruiting2021
A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics		Phase 3Not yet recruiting2026
A Randomized Double Blind Placebo Controlled MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004 TAB004) as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01 — cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics		Phase 3Active not recruiting2025
Study of pre and post surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE)
2023-507778-42-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, therapeutics		Phase 2Recruiting2023
Beamion 44 A study to test how well zongertinib is tolerated by people with advanced non small cell lung cancer with HER2 mutations when given in combination with chemotherapy with or without pembrolizumab
2025-523567-38-00 — cells, lung, safety, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy, her2 mutation		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS